Trial Profile
Multicenter Phase II Study of MK-2206 in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs MK 2206 (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 28 Jan 2016 Planned End Date changed from 1 May 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 28 Jan 2016 Planned primary completion date changed from 1 May 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 21 May 2014 Planned End Date changed from 1 May 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.